Perceptions of the medicinal value of hallucinogenic drugs among college students JARED I. WILDBERGER, CASSANDRA N. JOHN and ROBERT M. HALLOCK Journal of Psychedelic Studies, 2017, 1(2), pp. 50–54 DOI: 10.1556/2054.01.2017.008 Background : This survey examined perceptions among college students about the potential medicinal benefits of hallucinogenic drugs. Current research and potential benefits include an ability to help anxiety, post-traumatic stress disorder, and addiction with hallucinogen-assisted psychotherapy. Methods : We devised and administered a survey on 124 students at two college campuses, one small private college in the mid-Atlantic and one medium-sized public university in the Midwest of the United States. Results: Responses were similar [...]
Lire la suiteEffects of Schedule I drug laws on neuroscience research and treatment innovation. Nutt D.J., King L.A., Nichols D.E. Nature Reviews Neuroscience, 2013, 14, 577-585 DOI : 10.1038/nrn3530 Abstract Many psychoactive drugs are used recreationally, particularly by young people. This use and its perceived dangers have led to many different classes of drugs being banned under national laws and international conventions. Indeed, the possession of cannabis, 3,4‑methylenedioxy- N‑methyl-amphetamine (MDMA; also known as ecstasy) and psychedelics is stringently regulated. An important and unfortunate outcome of the controls placed on these and other psychoactive drugs is that they make research into their mechanisms of action and potential therapeutic [...]
Lire la suitePsychedelic drugs in the treatment of anxiety, depression and addiction Tor-Morten Kvam, Lowan H. Stewart & Ole A. Andreassen Tidsskriftet, Den Norske Legeforening, November 2018 https://www.researchgate.net/publication/332136512 B A C K G R O U N D There is growing interest in the use of psychedelic drugs for the treatment of mental disorders. The drugs are considered safe when administered within a clinical framework. Older studies performed prior to 1970 had methodological shortcomings, but studies in recent years have shown promising results regarding the use of psychedelic drugs in unipolar depression, depression in life-threatening illness, anxiety and addiction. The aim of this literature review is to [...]
Lire la suiteHow do hallucinogens work on the brain? Robin Carhart-Harris, Mendel Kaelen and David Nutt The Psychologist, 2014, 27, 9, 662-665 What do we know about how hallucinogens work on the brain to produce their characteristic subjective effects? This question can be approached from a number of different levels. At the lowest functionally relevant level, how do the hallucinogenic compounds themselves interact with a certain neurotransmitter receptor to alter neuronal activity? Then at the neuronal population level, how does a drug-induced change in neuronal firing interact with the integrated oscillatory activity of large populations of neurons? Finally, how does this all play out at [...]
Lire la suiteIntérêt de la psilocybine, de l’acide lysergique diéthylamide (LSD) et de la diméthyltryptamine (DMT) dans la dépression : une revue de la littérature THÈSE MÉDECINE SPÉCIALISÉE CLINIQUE en Psychiatrie Présentée et soutenue publiquement par Sami SERGENT le 22 février 2019 ANNÉE 2019 (2019 TOU3 1503) Directeur de thèse : Dr François MONTASTRUC JURY Monsieur le Professeur Christophe ARBUS Président Monsieur le Professeur Laurent SCHMITT Assesseur Monsieur le Professeur Nicolas FRANCHITTO Assesseur Monsieur le Docteur François MONTASTRUC Assesseur Madame le Docteur Bénédicte JULLIAN Suppléant Monsieur le Docteur Nicolas NAVARRO membre invité RESUME EN FRANÇAIS : La psilocybine, l’acide lysergique diéthylamide et la diméthyltryptamine sont des psychédéliques agonistes sérotoninergiques. Les sociétés humaines en font usages depuis [...]
Lire la suiteThe influence of therapists’ first-hand experience with psychedelics on psychedelic-assisted psychotherapy research and therapist training ELIZABETH M. NIELSON and JEFFREY GUSS Journal of Psychedelic Studies, 2018 DOI: 10.1556/2054.2018.009 Abstract Clinical research on psychedelic-assisted psychotherapy is rapidly advancing in the USA, with two drugs, psilocybin and MDMA, progressing through a structure of FDA-approved trials on a trajectory toward Drug Enforcement Agency rescheduling for therapeutic use. Researcher’s and clinician’s personal use of psychedelics was cited as a potential confound in psychedelic research studies conducted in the 1950s and 1960s, a concern which contributed to the cessation of this research for some 20 years. Currently, there is no [...]
Lire la suiteEDITORIAL Should addiction researchers be interested in psychedelic science ? Stephen Bright, Martin Williams & David Caldicott Australasian Professional Society on Alcohol and other Drugs, Drug and Alcohol Review, 2017 DOI: 10.1111/dar.12544 As recently noted by Strauss, Bright and Williams [1], while much of the Western world has been experiencing a renaissance in research into ‘psychedelic science’ over the past decade [2], there has been no such research conducted in Australia. In Europe and the USA, studies have been conducted into lysergic acid diethylamide (LSD) that have improved our understanding of brain function [3] and reduced existential anxiety associated with dying [4], while psilocybin-assisted psychotherapy has [...]
Lire la suiteThe psychedelic renaissance and the limitations of a White-dominant medical framework: A call for indigenous and ethnic minority inclusion JAMILAH R. GEORGE, TIMOTHY I. MICHAELS, JAE SEVELIUS and MONNICA T. WILLIAMS Journal of Psychedelic Studies, 2019 DOI: 10.1556/2054.2019.015 In recent years, the study of psychedelic science has resurfaced as scientists and therapists are again exploring its potential to treat an array of psychiatric conditions, such as depression, post-traumatic stress disorder, and addiction. The scientific progress and clinical promise of this movement owes much of its success to the history of indigenous healing practices; yet the work of indigenous people, ethnic and racial minorities, women, [...]
Lire la suiteREBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics R. L. Carhart-Harris and K. J. Friston Pharmacological Reviews, 2019, 71, 316–344 https://doi.org/10.1124/pr.118.017160 Significance Statement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 317 I. Introduction. . . . . . . . . . . . . . . . . . . . . . . . . [...]
Lire la suiteSpectral signatures of serotonergic psychedelics and glutamatergic dissociatives Carla Pallavicini, Martina G. Vilas, Mirta Villarreal, Federico Zamberlan, Suresh Muthukumaraswamy, David Nutt, Robin Carhart-Harris, Enzo Tagliazucchi NeuroImage, 2019 https://doi.org/10.1016/j.neuroimage.2019.06.053 Abstract Classic serotonergic psychedelics are remarkable for their capacity to induce reversible alterations in consciousness of the self and the surroundings, mediated by agonism at serotonin 5-HT2A receptors. The subjective effects elicited by dissociative drugs acting as N-methyl-D-aspartate (NMDA) antagonists (e.g. ketamine and phencyclidine) overlap in certain domains with those of serotonergic psychedelics, suggesting some potential similarities in the brain activity patterns induced by both classes of drugs, despite different pharmacological mechanisms of action. We investigated source-localized [...]
Lire la suite